The largest database of trusted experimental protocols

22 protocols using panobinostat

1

Cytotoxic Agents in Cancer Treatment

Check if the same lab product or an alternative is used in the 5 most similar protocols
Doxorubicin (Sigma, St. Louis, USA), 5-aza-2′-deoxycytidine (decitabine/5-AZA-CdR, Sigma), azacitidine (Celgene, Summit, NJ, USA), cisplatin (Sigma), gemcitabine (Sigma), etoposide (Sigma), docetaxel (Sigma), paclitaxel (Sigma), vinblastine (Sigma), panobinostat (Sigma), vorinostat (Sigma) and bortezomib (Sigma) were added from a stock solution to the 10% serum-containing RPMI medium (Gibco, Waltham, MA, USA). Doxorubicin, etoposide, docetaxel, paclitaxel, vinblastine, panobinostat, vorinostat and bortezomib were dissolved in dimethyl sulfoxide (DMSO; Sigma), cisplatin was dissolved in 10% DMSO (Sigma) in 10% serum-containing RPMI, and 5-AZA-CdR, azacitidine and gemcitabine were dissolved in distilled water. Dose calculation was based on human dosages and previous publications [10 (link)].
+ Open protocol
+ Expand
2

Preparation and Storage of Anticancer Drugs

Check if the same lab product or an alternative is used in the 5 most similar protocols
Paclitaxel, cisplatin, panobinostat (pano) and suberoylanilide hydroxamic acid (SAHA) were supplied in powdered form and stored at −20 °C (Table 1).
Paclitaxel and SAHA were supplied from Sigma-Aldrich (St. Louis, MO, USA). cisplatin and panobinostat were supplied from Cayman Chemical (Ann Arbor, MI, USA). Stock solutions of Paclitaxel, panobinostat, and SAHA were prepared using 100% dimenthyl sulfoxide (DMSO; Sigma-Aldrich). Aliquots were stored at −20 °C. cisplatin was prepared using sterile normal saline and stored at −4 °C. cisplatin solution was discarded at 30 days. All drug concentrations were taken from published IC50 concentrations relevant to each cell line, as demonstrated in Table 2.
+ Open protocol
+ Expand
3

Drug Formulation and Preparation Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Napabucasin, panobinostat, and quisinostat were purchased from Selleckchem and A1331852 and Navitoclax from Chemietek, diluted in DMSO to make stock solutions, aliquoted and stored at −80C. Napabucasin was formulated by heating to 50C for 10 minutes and then sequentially adding 45% PEG300 (Sigma), 5% Tween80 (Sigma) and 45% sterile water, with vortexing after adding each component (Selleckchem). panobinostat was formulated by sequentially adding 48% PEG300 (Sigma), 2% Tween80 (Sigma) and 48% sterile water, with vortexing after adding each component (Selleckchem). quisinostat was formulated in 10% hydroxypropyl-b-cyclodextrin (Sigma), 25 mg/ml mannitol (Sigma), in sterile water(45 (link)). A1331852 was formulated by sequentially adding 10% Ethanol (Fisher), 60% Phosal 50 PG (Lipoid), and 30% PEG400 (Sigma), and vortexing (MedChemExpress). Navitoclax was formulated in 10% ethanol (Fisher), 30% PEG400 (Sigma), and 60% Phosal 50 PG (Lipoid), with vortexing after adding each component (MedChemExpress). Sorafenib was formulated in 90% corn oil (Selleckchem) with vortexing (MedChemExpress). Working solutions were made fresh prior to administration.
+ Open protocol
+ Expand
4

Osteoclast Differentiation from Bone Marrow Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Total bone marrow cells from WT and GPR109A−/− mice were isolated by flushing the femora and tibiae. The cells were plated overnight at 37 °C with 5.5% CO2 in alpha minimum essential medium (αMEM), supplemented with 10% FBS and 1% penicillin/streptomycin (Gibco, Carlsbad, CA, USA), and 40 ng/ml macrophage colony stimulating factor (M-CSF; R&D Systems). Next day, nonadherent cells were collected and cultured in osteoclast medium with 40 ng/ml M-CSF and 50 ng/ml receptor activator of nuclear factor kappa-B (NF-κB) ligand (RANKL; R&D Systems) in 24-well plates (for tartrate-resistant acid phosphatase (TRAP) staining, immunofluorescence), 12-well plates (for RNA isolation), or 6-well plates (for Western blotting) at a density of 1 × 106 cells/ml at 37 °C and 5.5% CO2. The medium was changed every 3 d. In SCFA experiments, preosteoclasts in C3 and C4 groups were further stimulated on day 1 of culture with the following stimulants: 5 mmol/L propionate, 1 mmol/L butyrate (Sigma-Aldrich), 40 ng/ml IL-1β (MedChemExpress), 50 nmol/L TSA (MedChemExpress), 25 nmol/L Panobinostat (Sigma-Aldrich), 100 μmol/L 4-CMTB (Sigma-Aldrich), 1 mmol/L niacin (MedChemExpress), or 25 μmol/L AR42062 (Sigma-Aldrich). Then, fully differentiated osteoclasts (days 5–7) were collected for PCR, Western blotting, TRAP staining, and immunofluorescence staining.
+ Open protocol
+ Expand
5

Lung Cancer Cell Lines Viability Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
Human lung cancer cell lines A549 (ATCC Cat#: CCL-185), NCI-H23 (ATCC Cat#: CRL-5800), NCI-H1299 (ATCC Cat#: CRL-5803), NCI-H441 (ATCC Cat#: HTB-174), HCC827 (ATCC Cat#: CRL-2868), NCI-H1975 (ATCC Cat#: CRL-5908) and NCI-H2172 (ATCC Cat#: CRL-5930) were obtained from American Type Culture Collection (ATCC) and cultured as instructed. The human lung cancer PC14 cell line was kindly provided by Mr. Yu (The Shanghai Cancer Institute, China). The cancer cells were maintained in Roswell Park Memorial Institute (RPMI)1640 medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin and streptomycin (all from Invitrogen). Cells were maintained under a standard gas atmosphere of humidified air/5% CO2.
Cell growth was measured using CellTiter-Glo (Promega). The cells were seeded in 96-well plates in 100 μl of medium with different drug doses. Cisplatin (C2210000, Sigma Aldrich) and panobinostat (EPI009, Sigma Aldrich) were dissolved in dimethyl sulfoxide (DMSO). After the cells were cultured for 48 hours, 100 μl of CellTiter-Glo reagent was added to each well to measure cell growth according to the manufacturer's instructions.
+ Open protocol
+ Expand
6

Multifaceted Cell Death Pathway Modulation

Check if the same lab product or an alternative is used in the 5 most similar protocols
Indicated chemicals were obtained from companies (in parentheses): brefeldin A (Sigma-Aldrich), golgicide A (Sigma-Aldrich), AG1478/tyrphostin (Sigma-Aldrich), Erastin (MedChem Express), ferrostatin-1 (Sigma-Aldrich), liproxstatin-1 (Sigma-Aldrich), NOX1/4 inhibitor (GKT137831, Cayman Chemical), Sulfasalazine (Sigma-Aldrich), Sorafenib (Sigma-Aldrich), RSL3 (MedChem Express), Glutathione (Sigma-Aldrich), N-acetyl-cysteine (Sigma-Aldrich), Ciclopirox olamine (CPX, Sigma-Aldrich), LOXi (PD-146176, Santa Cruz Biotechnology), Trolox (Sigma-Aldrich), Prankulast (Biomol), tunicamycin (Sigma-Aldrich), Erastin (MedChemExpress), BSO (Santa Cruz Biotechnology), cisplatin (Santa Cruz Biotechnology), doxorubicin (Sigma-Aldrich), 2-ME (Sigma-Aldrich), PPG (Sigma-Aldrich),
Nutlin-3 (Sigma-Aldrich), vildagliptin (Sigma-Aldrich), Q-VD-OPh hydrate (Sigma-Aldrich), bafilomycin A (Sigma-Aldrich), nocodazole (Sigma-Aldrich), panobinostat (Sigma-Aldrich), doxorubicin (Sigma-Aldrich). AMF-26 was synthesized by Merck KGaA23 (link).
+ Open protocol
+ Expand
7

Cell Viability Assay with HDAC and DOT1L Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols
The HDAC inhibitors Panobinostat (Sigma) and Vorinostat (Sigma) and the DOT1L inhibitors Pinometostat (EPZ-5676) (Selleck Chemicals) and SGC-0946 (Selleck Chemicals), and DMSO (Sigma) were diluted in culture medium. First, the inhibitors were diluted in culture medium to a stock concentration that was twice as high as the highest concentration tested. The stock concentration was further diluted to obtain to the desired range of concentrations. Twenty-thousand cells were plated per well in a flat-bottom culture-treated 96 wells plate, in 50 µl culture medium and 50 µl culture medium with inhibitor was added. Four hours before measuring cell viability, Cell Titer Blue (Promega) was added to the wells and cells were incubated in the dark at 37°C under 5% CO2 conditions. After 4 hours, fluorescence was measured on the EnVision Multilabel Reader (Perkin Elmer). In order to calculate cell viability, values for fluorescence intensity of each condition were normalized against those of untreated cells. Each biological replicate represents an average of three technical replicates of an independent experiment.
+ Open protocol
+ Expand
8

Synthesis of DCZ0814 Compound

Check if the same lab product or an alternative is used in the 5 most similar protocols
DCZ0814 (methyl ((4-(3,5-dimethoxystyryl)phenoxy)(4-(2-hydroxybenzamido)phenoxy)phosphoryl)-L-prolinate) was synthesized by the Shanghai Institute of Materia Medica (Chinese Academy of Sciences, Shanghai, China). Bortezomib, panobinostat and dexamethasone were purchased from Sigma–Aldrich (St. Louis, MO, USA). IL-6 and IGF-1 were obtained from R&D Systems (Minneapolis, MN, USA).
+ Open protocol
+ Expand
9

Evaluating HDAC Inhibitors in T Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Jurkat T cells (Clone E6-1) were obtained from the American Tissue Culture Collection. J-Lat 10.6 cells were obtained from the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH (contributed by Dr. Eric Verdin; Jordan et al., 2003 (link)). Cells were cultured in R10+ media [RPMI 1640 with HEPES and L-Glutamine, 10% fetal bovine serum, 100 U of penicillin/ml, and 100 µg of streptomycin/ml (Sigma)] and incubated at 37°C and 5% CO2.
HDAC-Glo I/II Assay kits were obtained from Promega. Panobinostat was obtained from Sigma-Aldrich. Compounds 15, 16 and 17, and 18 were purchased from Sellick Chemical, Enamine, and Molport, respectively. Serpulanine A was gratefully obtained as a gift from Dr. Raymond J. Andersen (University of British Columbia). Compounds stocks were diluted in DMSO and stored at minus 20°C until use.
+ Open protocol
+ Expand
10

Cardiac Electrophysiology Assay Using hiPSC-CMs

Check if the same lab product or an alternative is used in the 5 most similar protocols
All drugs were obtained from Sigma Aldrich: vanoxerine (Cat. D052), cisapride (C4740), dofetilide (PZ0016), nifedipine (N7634), as well as the following histone deacetylase inhibitors, HDACi: 4-phenylbutyrate, 4PB (567616), tubastatin A (SML0044) and from a kit (EPI009-1KT): trichostatin-A (TSA), panobinostat, and SAHA. The drugs were dissolved in DMSO (Cat. 34869, Sigma-Aldrich), except for 4PB (dissolved in sterile water) and stored in −20°C until ready for application on the hiPSC-CMs. The HDAC inhibitors TSA, panobinostat, 4PB, tubastatin, and SAHA stock solutions were diluted in hiPSC-CM maintenance media and applied to the cells 48 hours prior to functional measurements. vanoxerine, cisapride, dofetilide, and nifedipine stocks were diluted in Tyrode’s solution on experimental day and applied for 30 minutes at 37°C, 5% CO2 prior to functional experiments. Drug concentrations are as specified in the figures, and all were selected to be at 1X to 10X of the effective free therapeutic plasma concentrations, ETPC, see Table 1.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!